# PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

> **NCT06533384** · PHASE3 · RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 310 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Camrelizumab is made for adjuvant therapy.
- **DRUG:** 9 cycles of Camrelizumab as adjuvant therapy.

## Key facts

- **NCT ID:** NCT06533384
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533384, "PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06533384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*